New TPK 2100 Critical Flow Controller for dry powder inhaler testing

5 Dec 2017

A highly automated system to speed up testing, improve reproducibility, and enhance data output and recording.

Copley Scientific will be presenting its new 3rd generation Critical Flow Controller – the TPK 2100 – for the testing of dry powder inhalers (DPIs) at the 2017 Drug Delivery to the Lungs conference (DDL2017) in Edinburgh. The company is showcasing this latest TPK model to highlight a series of new capabilities, all intended to make dry powder inhaler testing more automated, more reproducible and more efficient.

New TPK 2100 Critical Flow Controller for dry powder inhaler testing

The newly introduced TPK 2100 builds on Copley’s heritage of TPK models, an international standard in the field of DPI testing equipment, and is ideally suited to the needs of formulators and quality control scientists. It sets a new benchmark for the set-up, control and documentation of all the parameters associated with the measurement of delivered dose uniformity and aerodynamic particle size distribution (APSD) by cascade impaction, in accordance with the US and European Pharmacopoeias.

Anna Sipitanou, Business Development Manager at Copley Scientific, comments: “The new TPK 2100 has already generated extremely positive feedback from customers who have interacted with it, both at RDD Europe back in April and since its launch. We think it will be a big hit at DDL, as we give live demonstrations to inhaler testing analysts and laboratory managers alike. It is rewarding to know that the advancements we have incorporated into the TPK 2100 look set to benefit both existing and new customers, making a substantial difference to productivity and efficiency in the execution of these important tests.”

Designed to replace the well-established TPK 2000, significant new features are built into the TPK 2100. A new ‘fly-by-wire’ flow control valve allows operation to be automated. Inhaler pressure drop, P1, and test flow rate are accurately and rapidly set by the TPK 2100 during test set-up, whilst in-line flow measurement can be accommodated and in-situ impactor leak testing is fully automated for the first time. The user is warned if the important P3/P2 ratio is greater than 0.5, giving full confidence that tests are conducted under sonic flow conditions, whilst notification is also given if the set flow rate and impactor leak rate are outside acceptance limits. Test duration is automatically calculated based on the required test volume, and the new model offers an optional footswitch and temperature/humidity module. Data output to printer and computer are standard, with enhanced monitoring and 5 different reports covering critical in-test parameters, whilst remote control via USB allows the TPK 2100 to be integrated into larger automated systems, where required. Finally, the new instrument allows users to emulate the previous generations of TPK, promoting interchangeability and integration into existing standard operating procedures (SOPs).

A new TPK 2100-R is also being launched. This is a reversed version where the flow inlet and outlets are swapped over to allow for different arrangements of testing equipment to be set up on the laboratory bench.

Read More

Related news

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Take part in pharma’s largest reputation survey

Take part in pharma’s largest reputation survey

6 Sep 2019

Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Read more 
Meet Avivia / Excipia at booth B56 Hall 12.1 CPhI Frankfurt 2019

Meet Avivia / Excipia at booth B56 Hall 12.1 CPhI Frankfurt 2019

29 Aug 2019

Meet Avivia at booth B56 Hall 12.1 CPhI Frankfurt 2019

Read more 
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

16 Aug 2019

Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.

Read more 
Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

5 Aug 2019

Opportunities abound at CPhI MEA and experts anticipate regional generic companies acting as CMOs for international companies looking to enter the region.

Read more 
Drive for generics sees Korea increasingly attractive to international pharma

Drive for generics sees Korea increasingly attractive to international pharma

31 Jul 2019

Korean companies are opening more facilities overseas and using CPhI Korea to look for new international partners.

Read more 
Huge CPhI & P-MEC China a direct result of surging manufacturing

Huge CPhI & P-MEC China a direct result of surging manufacturing

22 Jul 2019

Great Hall of China: Informa adds additional capacity to Asia’s largest pharma event with record 66,000+ visits from 141 countries.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Piramal expands its high potency API capability

Piramal expands its high potency API capability

25 Jun 2019

Becomes one of only a few companies in the contract development and manufacturing market that can produce HPAPIs at such low OELs.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more